SCHEMBL30459638

SCHEMBL30459638

Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1N1CCC(N2CCNCC2)CC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 20/20 0.80
▸ INSR P06213 10/20 0.71
▸ KCNH2 Q12809 4/20 0.71
▸ FGFR2 P21802 3/20 0.71
▸ FGFR4 P22455 3/20 0.71
▸ FGFR3 P22607 3/20 0.71
▸ ROS1 P08922 3/20 0.71
▸ PTK2 Q05397 3/20 0.71
▸ PLK4 O00444 2/20 0.71
▸ JAK2 O60674 2/20 0.71
▸ ROCK2 O75116 2/20 0.71
▸ ABL1 P00519 2/20 0.71
▸ EGFR P00533 2/20 0.71
▸ NTRK1 P04629 2/20 0.71
▸ LCK P06239 2/20 0.71
▸ FES P07332 2/20 0.71
▸ LYN P07948 2/20 0.71
▸ RET P07949 2/20 0.71
▸ IGF1R P08069 2/20 0.71
▸ MET P08581 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30459769 0.93 ALK (0.89) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL30459649 0.88 ALK (0.75) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL30924829 0.87 ALK (0.76) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL30761548 0.86 ALK (0.87) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL28619135 0.86 ALK (0.87) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL14780839 0.85 ALK (0.73) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL21478104 0.85 ALK (0.87) ALKINSRFGFR2FGFR4FGFR3
SCHEMBL28619123 0.85 ALK (0.87) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL31100375 0.84 ALK (0.62) ALKINSRKCNH2FGFR2FGFR4
SCHEMBL31100798 0.84 ALK (0.59) ALKINSRKCNH2FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4745138-A1 THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-05-20 — — EP disclosed
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 — — EP disclosed
WO-2024245443-A1 COMPOUND BASED ON OXOISOINDOLINYL SUBSTITUTED TETRAHYDRO-2-PYRIMIDONE, AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-12-05 — — WO disclosed
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 — — EP disclosed
WO-2024188209-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-09-19 — — WO disclosed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 — — WO disclosed
Send feedback